Dr Sarah Best and Dr Kate Sutherland (IMAGE)

Walter and Eliza Hall Institute

Dr Sarah Best and Dr Kate Sutherland

Caption

Dr Sarah Best (left) and Dr Kate Sutherland (right) from the Walter and Eliza Hall Institute in Melbourne, Australia, have shown that co-existing mutations in KRAS-positive lung cancers can give the tumour distinctive characteristics which they have successfully targeted to inhibit cancer growth. The study suggests this tactic should be investigated for targeted treatment of KRAS-positive human lung adenocarcinomas.

Credit

Walter and Eliza Hall Institute

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.